AA
ATRS

ALPS Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

ALPS Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-102,178
Closed -$365K – 1032
2021
Q4 		$365K Buy
102,178
+2,044
+2% +$7.15K ﹤0.01% 745
2021
Q3 		$364K Buy
+100,134
New +$405K ﹤0.01% 667

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

ALPS Advisors's ATRS Position: Q1 2022 in Review

ALPS Advisors sold out of Antares Pharma, Inc. (ATRS) in Q1 2022, closing a stake of 102,178 shares — an estimated $365K sold.

ALPS Advisors first reported a position in ATRS in Q3 2021 and held it in 2 quarters. The position peaked at $365K in Q4 2021. 177 funds tracked by Wall St. Rank hold ATRS as of Q1 2022.

  • ALPS Advisors reported no remaining Antares Pharma, Inc. position as of Q1 2022 after selling out during the quarter.
  • ALPS Advisors sold 102,178 Antares Pharma, Inc. shares in Q1 2022, an estimated $365K.
  • ALPS Advisors first reported a position in Antares Pharma, Inc. in Q3 2021 and held it in 2 quarters.
  • ALPS Advisors's Antares Pharma, Inc. position peaked at $365K in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2022.

Based on ALPS Advisors's 13F filing for Q1 2022, filed 16 May 2022.